Cell Biotech has been growing earnings at an average annual rate of 14%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 2.9% per year. Cell Biotech's return on equity is 10.1%, and it has net margins of 23.7%.
How Cell Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A049960 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
56,494
13,407
24,843
3,850
31 Dec 25
53,126
10,125
23,940
3,883
30 Sep 25
50,649
12,592
23,559
4,289
30 Jun 25
47,456
10,112
21,279
4,294
31 Mar 25
48,104
13,935
20,441
4,138
31 Dec 24
49,913
15,127
21,848
4,332
30 Sep 24
52,600
10,974
22,371
3,971
30 Jun 24
54,097
12,966
23,928
4,070
31 Mar 24
53,980
6,708
29,398
4,034
31 Dec 23
53,787
6,304
29,845
3,725
30 Sep 23
52,751
166
30,941
3,544
30 Jun 23
51,509
2,736
29,847
3,457
31 Mar 23
51,272
8,128
26,595
3,510
31 Dec 22
50,526
8,281
25,278
3,559
30 Sep 22
48,754
14,642
23,407
3,712
30 Jun 22
49,081
12,997
22,932
3,627
31 Mar 22
48,328
10,632
22,284
3,677
31 Dec 21
46,873
10,383
21,987
3,500
30 Sep 21
45,761
6,032
22,512
3,181
30 Jun 21
44,196
3,270
23,576
3,207
31 Mar 21
44,156
2,942
24,165
3,243
31 Dec 20
45,582
3,189
24,641
3,329
30 Sep 20
46,990
5,900
24,787
3,800
30 Jun 20
46,333
6,472
24,345
3,856
31 Mar 20
46,582
8,017
23,826
3,673
31 Dec 19
45,960
7,231
23,697
3,704
30 Sep 19
49,346
11,379
22,796
3,421
30 Jun 19
53,473
13,585
22,518
3,419
31 Mar 19
58,136
16,544
22,454
3,362
31 Dec 18
62,544
19,384
22,435
3,433
30 Sep 18
60,324
16,525
22,830
3,369
30 Jun 18
61,301
17,865
22,970
3,271
31 Mar 18
62,295
19,802
21,916
3,156
31 Dec 17
61,057
18,198
21,497
2,886
30 Sep 17
62,706
20,756
22,242
2,908
30 Jun 17
58,937
18,581
20,885
2,880
31 Mar 17
57,150
17,071
19,618
2,945
31 Dec 16
58,276
18,499
20,097
2,918
30 Sep 16
55,048
17,719
16,941
3,047
30 Jun 16
57,418
21,705
16,464
3,064
31 Mar 16
55,230
20,603
17,162
2,838
31 Dec 15
49,505
17,505
15,602
2,844
30 Sep 15
49,291
16,582
17,259
2,386
Quality Earnings: A049960 has a high level of non-cash earnings.
Growing Profit Margin: A049960's current net profit margins (23.7%) are lower than last year (29%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A049960's earnings have grown by 14% per year over the past 5 years.
Accelerating Growth: A049960's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A049960 had negative earnings growth (-3.8%) over the past year, making it difficult to compare to the Biotechs industry average (22.6%).
Return on Equity
High ROE: A049960's Return on Equity (10.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/27 21:18
End of Day Share Price
2026/07/27 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cell Biotech Co., Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.